Clinical Trial Update: Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated how aliskiren, ramipril, and their combination affect angiotensin II levels in patients with decompensated systolic heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Ramipril (ramipril)
• Tekturna (aliskiren)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure | Phase 2 | Status: COMPLETED | Results posted: 2012-03-05